Investor Presentaiton

INVESTOR 20 DAY 23 4 What kind of therapy is best for me? Colorectal Cancer Expanded patient eligibility for targeted therapy through promoter methylation Epigenomics unlocks mechanisms of regulation that are invisible to genomic testing MLH1 Promoter Methylated MLH1 Samples cancer type 3 37033671 3 37033791 3 37033861 3 37033804 3 37033911 3 37033971 3 37034008 3 37034031 3 37034091 3 37034129 3 37034151 3 37034211 37034246 3.37034271 3 37034331 3.37034364 3 37034391 337034451 Loci 3 37034478 3 37034511 3.37034571 3 37034509 3 37034631 MLH1 promoter methylation identified additional 7% of MSI-H patients missed by genomic testing alone. 3 37034691 3 37034716 337034751 3 37034811 3.37034871 3 37034031 3 37034947 3 37035051 3 37035068 These patients would be 3 37035111 3 37035171 3 37035184 3 37035231 3 37035291 3 37035302 eligible for FDA-approved I/O therapy options.1 GUARDANT™ MSI-H-Micro-satellite instability, High 1 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125514s096lbl.pdf 88 38

View entire presentation